数据
资源
版本对比
免费注册
预约演示
免费注册
Age-related Macular Degeneration
Pipeline Analysis of 70+ Key Companies and 70+ Key Therapeutic Products
2021-03-09
·
GlobeNewswire
抗体
生物类似药
合作
Los Angeles, USA , March 09, 2021 (GLOBE NEWSWIRE) --
Age-related Macular Degeneration
Pipeline Analysis of 70+ Key Companies and 70+ Key Therapeutic Products DelveInsight anticipates the launch of
ABP 938
,
KSI-301
,
OPT-302
, and
RGX-314
in the
Age-related Macular Degeneration
Pipeline as the most promising therapies. DelveInsight’s
Age-related Macular Degeneration (AMD)
Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the
AMD
domain. The
AMD
AMD
Pipeline Analysis report offers a 360° view of the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA for
Age-related Macular Degeneration
emerging therapies. The
Age-related Macular Degeneration
Pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies. Some of the key takeaways from the
Age-related Macular Degeneration
Pipeline report: Request for Sample @
Age-related Macular Degeneration
Pipeline Insights
Age-related Macular Degeneration
is a condition that impairs a small central area, macula, located at the center of the retina. It affects a person's central vision due to the formation of distorted, dark spots that gradually progress, thus, affecting the tasks like reading, and diving. Genetic mutations in- and around several complement gene systems, including the
CFH
gene, contribute to the risk of developing
AMD
. Further, changes on the long (q) arm of chromosome 10 in a region known as 10q26 are also associated with an increased risk of
Age-related Macular Degeneration
. Reach out for rich pipeline insights @
Age-related Macular Degeneration
Drug Pipeline
Age-related Macular Degeneration
Drug Profiles KSI 301:
Kodiak Sciences
KSI 301
is an antibody biopolymer conjugate for the treatment of
retinal vascular diseases
. It is a novel anti-
VEGF
biologic designed to rapidly inhibit
VEGF
and provide extended durability of action to reduce the burden of frequent anti-
VEGF
injections.
Kodiak
Sciences is currently evaluating
KSI 301
in Phase II/ III trial to evaluate its efficacy and safety versus
Aflibercept
in patients with
Neovascular (Wet) Age-Related Macular Degeneration
.
Kodiak Sciences
initiated a randomized, double-masked, active comparator-controlled, multi-center study (NCT04049266) to investigate the efficacy and safety of repeated intravitreal administration of
KSI-301
in subjects with
Neovascular (Wet) Age-related Macular Degeneration
. For more information on drug profiles, visit
Age-related Macular Degeneration
Emerging Therapies Key
Age-related Macular Degeneration
Pipeline
Age-related Macular Degeneration
Therapeutic Assessment By Product Type By Stage By Route of Administration By Molecule Type By Mechanism of Action By Targets By Stage and Molecule TypeBy Stage and Route of AdministrationBy Stage and Product Type Dive deeper into
Age-related Macular Degeneration
Therapeutic Assessment Scope of the Report Coverage: GlobalKey Players:
Amgen
,
Roche
,
Adverum Biotechnologies
,
AsclepiX Therapeutics
, Bioeq/Formycon,
Sinocelltech
,
RemeGen
,
Alkahest
,
Kyowa Kirin
,
EyePoint Pharmaceutical
,
IVERIC bio
,
Kodiak Sciences
,
Ribomic USA Inc
,
Sunshine Guojian Pharmaceutical
(Shanghai),
Lineage Cell Therapeutics
,
Graybug Vision
,
Sinocelltech
,
Luxa Biotechnology
, CHABiotech,
Shanghai Henlius Biotech
,
Bio-Thera Solutions
,
Alteogen
,
Samsung Bioepis
,
Outlook Therapeutics
,
Unity Biotechnology
,
Stealth BioTherapeutics
,
AiViva BioPharma
,
Ocular Therapeutix
, AO GENERIUM,
Gyroscope Therapeutics
,
Ionis Pharmaceuticals
,
Aerie Pharmaceuticals
,
Outlook Therapeutics
, and several others. Key
AMD
Pipeline Therapies:
Aflibercept
biosimilar,
Faricimab
, ADVM 022, AXT 107,
Ranibizumab
biosimilar, SCT510A, RC 28 E,
ALK4290
,
KHK4951
,
EYP-1901
, Zimura, RBM-007 Injectable Solution, Drug 601, OpRegen, KSI 301, ABP 938, ADVM-022, SCT510A, GB-102, RPESC-RPE-4W,
MA09-hRPE
,
SCD411
, HLX04-O,
BAT5906
,
LY09004
, ASP7317 among others. Key Questions Answered Got queries? Reach out to us @
Age-related Macular Degeneration
Drug Pipeline Table of Contents Related Reports
Age-Related Macular Degeneration
MarketDelveInsight's "
Age-Related Macular Degeneration
- Market Insights, Epidemiology, and Market Forecast-2030" report.
Dry Age Macular Degeneration
MarketDelveInsight's "
Dry Age Macular Degeneration
Market Insights, Epidemiology, and Market Forecast-2030" report
Wet Age-Related Macular Degeneration
MarketDelveInsight's "
Wet Age-Related Macular Degeneration (Wet AMD)
Market Insights, Epidemiology, and Market Forecast-2030" report.
Vernal Keratoconjunctivitis
MarketDelveInsight's "
Vernal keratoconjunctivitis
Market Insights, Epidemiology, and Market Forecast-2030" report.
Allergic Conjunctivitis
MarketDelveInsight's "
Allergic Conjunctivitis
Market Insights, Epidemiology, and Market Forecast-2030" report
Allergic Rhino-Conjunctivitis
MarketDelveInsight's "
Allergic Rhino-Conjunctivitis
Market Insights, Epidemiology, and Market Forecast-2030" report.
Anterior Uveitis
MarketDelveInsight's "
Anterior Uveitis
Market Insights, Epidemiology, and Market Forecast-2030" report.
Bacterial Conjunctivitis
MarketDelveInsight's "
Bacterial Conjunctivitis
Market Insights, Epidemiology, and Market Forecast-2030" report. Blepharitis MarketDelveInsight's "Blepharitis Market Insights, Epidemiology, and Market Forecast-2030" report.
Central Retinal Vein Occlusion
MarketDelveInsight's "
Central Retinal Vein Occlusion
Market Insights, Epidemiology, and Market Forecast-2030" report. Central Serous Chorioretinopathy MarketDelveInsight's "
Central Serous Chorioretinopathy
Market Insights, Epidemiology, and Market Forecast-2030" report.
Choroidal Neovascularization
MarketDelveInsight's "
Choroidal Neovascularization
Market Insights, Epidemiology, and Market Forecast-2030" report.
Corneal Endothelial Dystrophy
MarketDelveInsight’s ‘
Corneal Endothelial Dystrophy (CED)
Market Insights, Epidemiology, and Market Forecast—2030’ report.
Diabetic Retinopathy
MarketDelveInsight’s ‘
Diabetic Retinopathy (DR)
Market Insights, Epidemiology, and Market Forecast—2030’ report. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports
Pharma
companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
机构
Aiviva Biopharma, Inc.
EyePoint Pharmaceuticals, Inc.
Kodiak Sciences, Inc.
[+27]
适应症
黄斑变性
II型糖原贮积病
血管疾病
[+12]
靶点
CFH
VEGF
药物
Sozinibercept
阿柏西普生物类似药 (山东博安生物)
阿柏西普
[+11]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务